Business Context and Reporting Period
This Form 8-K is a current report filed by Protalix Biotherapeutics, Inc. on October 26, 2011. The filing serves as a Regulation FD disclosure to announce upcoming presentations by senior management at four industry conferences scheduled between November and December 2011.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly informational regarding corporate events and does not contain financial statements or performance data.
Material Changes
No material financial changes or operational updates are reported in this document. The filing solely discloses the schedule of future management presentations.
Guidance, Outlook, and Management Commentary
Management has scheduled presentations to discuss the following topics:
- Ernst & Young Journey 2011 Conference (Nov 2, 2011): The Pfizer-Protalix Gaucher Collaboration – The Partners' Point of View (Dr. David Aviezer, President & CEO).
- PDA/FDA Conference (Nov 3, 2011): Potential Safety and Quality Issues Related to Plants and Plant-Based Products (Dr. Yoseph Shaaltiel, Executive Vice President, R&D).
- Lazard Capital Markets 8th Annual Healthcare Conference (Nov 16, 2011): Corporate Presentation (Mr. Yossi Maimon, CFO). A webcast and 30-day replay will be available.
- World Orphan Drug Congress (Dec 1, 2011): Regulatory Expectations and Clinical Strategy for Treating Fabry Disease (Dr. David Aviezer, President & CEO).
Investor Verification Checklist
- Verify the content of the press release furnished as Exhibit 99.1 for any additional details not summarized here.
- Check the company website (www.protalix.com) for the webcast replay of the Lazard Capital Markets presentation after November 16, 2011.
- Review subsequent filings for financial results, as this 8-K contains no financial data.